ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

ALTH Allos Therapeutics, Inc. (MM)

1.83
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Allos Therapeutics, Inc. (MM) NASDAQ:ALTH NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 1.83 0 01:00:00

Weinstein Kitchenoff Scarlato Karon & Goldman Ltd. Announces Class Action Lawsuit Against Allos Therapeutics, Inc.

21/05/2004 11:00pm

PR Newswire (US)


Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more Allos Therapeutics, Inc. (MM) Charts.
Weinstein Kitchenoff Scarlato Karon & Goldman Ltd. Announces Class Action Lawsuit Against Allos Therapeutics, Inc. PHILADELPHIA, May 21 /PRNewswire/ -- The law firm of Weinstein Kitchenoff Scarlato Karon & Goldman Ltd. announced today that a class action lawsuit has been filed on behalf of purchasers of Allos Therapeutics, Inc. publicly traded securities between May 29, 2003 and May 3, 2004 (the "Class Period"). The complaint alleges that Defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. Specifically the complaint alleges that Allos misled the investing public by issuing a series of materially false and misleading statements highlighting the purported efficacy of the Company's radiation sensitizer RSR13 ("Efaproxiral") for the treatment of brain metastases in patients with breast cancer, as well as the likelihood that this drug would receive approval from the U.S. Food and Drug Administration ("FDA"). On April 30, 2004 and May 3, 2004, it was announced by the Oncologic Drugs Advisory Committee ("ODAC") of the FDA that it concluded by a 16-1 vote to recommend that the FDA not approve Efaproxiral. In recommending rejection of Efaproxiral, the ODAC found that, "the evidence of drug efficacy needs to be much stronger to be convincing." As a result of this announcement, the price of Allos shares fell $2.09, or 45% to close at $2.55 on extraordinary volume. If you bought Allos publicly traded securities between May 29, 2003 and May 3, 2004, and you wish to serve as lead plaintiff, you must file a request with the Court no later than July 19, 2004. Any member of the Class may file a request to serve as lead plaintiff through Weinstein Kitchenoff Scarlato Karon & Goldman Ltd. or other counsel of their choice, or may choose to do nothing and remain a member of the Class. The attorneys at Weinstein Kitchenoff Scarlato Karon & Goldman Ltd. (http://www.wkskg.com/) are experienced in representing defrauded investors in class actions in courts throughout the United States. The firm has achieved a total of more than $1 billion in recoveries for investors, consumers, and other victims of unlawful conduct. If you would like to consider serving as a lead plaintiff or have any questions about the lawsuit, please contact us by email at or toll-free at 877/805-7200. DATASOURCE: Weinstein Kitchenoff Scarlato Karon & Goldman Ltd. CONTACT: Weinstein Kitchenoff Scarlato Karon & Goldman Ltd., +1-877-805-7200, Web site: http://www.wkskg.com/

Copyright

1 Year Allos Therapeutics, Inc. (MM) Chart

1 Year Allos Therapeutics, Inc. (MM) Chart

1 Month Allos Therapeutics, Inc. (MM) Chart

1 Month Allos Therapeutics, Inc. (MM) Chart